Adverse Event reporting information can be found in footer
Request a Meeting
CORTIMENT® is coated with a gastro-resistant film, delaying budesonide release until a pH >7. This protects budesonide during transit through the stomach and duodenum up to the lower part of the intestine.3
Inside the tablet, budesonide is mixed with a hydrophilic matrix. Once the tablet comes into contact with the intestinal fluids it swells.3
The hydrophilic matrix gradually dissolves resulting in the release of budesonide from the inert lilophilic matrices in a controlled fashion throughout the entire colon.3
Protects active ingredient from degradation in upper GI tract and delays its release until the tablet reaches the colon.
Interacts with GI fluids to form an outer viscous gel mass, which slows diffusion of active ingredient from core.
Slows penetration of GI fluids into tablet core.
GI = gastrointestinal
Enables targeted delivery of
CORTIMENT® to the full length
of the colon.
A single-dose pharmacokinetic study
demonstrated that CORTIMENT®‘s colonic
release system is suitable for targeting
the whole colon.
Helps delay and extend the release
Budesonide MMX® was detected by
scintigraphic imaging in the ascending
colon between 4 and >24 hours after
Active substances are protected from
the acidic pH and enzymes of the upper
MMX = multimatrix
Adapted from Brunner M, et al. Br J Clin Pharmacol. 2006;61:31-8.
Adapted from Data on file. Ferring UK Ltd. 7
Job Code: UK-COR-2200001 - Date of preparation: January 2022